The known molecular pathogenesis of CML has facilitated the development of ABL-specific tyrosine kinase inhibitors (TKIs), such as imatinib (first generation), dasatinib, nilotinib, bosutinib (second generation) and ponatinib (third generation).4 The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.